Abstract: An apparatus for detecting and treating abnormal electrical conducting tissue of an organ of the body which comprises a catheter insertable within a blood vessel or body cavity into proximity with the organ to be treated. An electrode or other electrical field-producing element is carried within the catheter and is effective to produce an electric field capable of inducing abnormal movement of the organ, e.g., a cardiac arrhythmia, when the electrode is placed at or near the focus of the abnormal electrical conducting tissue of the organ. A relatively undistorted image of such abnormal tissue is obtained using optical phase conjugation of a low energy laser beam which is directed to the focus of the damaged tissue and the along one or more optic fibers carried within the catheter to a viewing apparatus. A laser beam transmitted through another optic fiber carried within the catheter is then employed, if necessary, to destroy the damaged tissue.

Abstract: A laser optic device comprises at least one optic fiber disposed within a protective conduit which is mounted to a disposable probe assembly having a hollow needle insertable within the body. Laser energy is transmitted through the optic fiber to a lens at one end which is adapted to focus the laser energy through the hollow needle and into a blood vessel, for creating a blood clot, or into the tissue immediately adjacent a damaged blood vessel for creating white scar tissue thereby causing the vessel to shrink in size and at least partially disappear from view.

Abstract: This disclosure describes novel substituted benzylideneaminoguanidines useful as anti-hypertensive agents and as diuretics.

Abstract: This disclosure describes novel substituted benzylideneaminoguanidines useful as anti-hypertensive agents and as diuretics.

Abstract: This invention concerns novel 3-[(3-alkylamino-2-hydroxypropoxy)phenyl]-1,2-propanediols of the formula: ##STR1## wherein R is selected from the group consisting of straight or branched-chain lower alkyls (C.sub.1 -C.sub.6) and cycloalkyls (C.sub.1 -C.sub.6); R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen and 2,3-dihydroxypropyl, with the proviso that R.sub.1 and R.sub.2 may not be the same; and R.sub.3 is selected from the group consisting of lower alkyls (C.sub.1 -C.sub.4) and lower alkoxys (C.sub.1 -C.sub.4); and the acid addition salts thereof. These novel compounds are useful as antiarrhythmic agents and .beta.-andrenergic blockers in mammals.This invention also concerns novel compounds of the formula ##STR2## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen and 2,3-dihydroxypropyl, with the proviso that R.sub.1 and R.sub.2 may not be the same; R.sub.3 is selected from the group consisting of lower alkyls (C.sub.1 -C.sub.4) and lower alkoxys (C.sub.